ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy –– ARV-102 ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in ...

ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy - - ARV-102 was well tolerated across all dose levels following 28 ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today ...

Herantis Pharma Plc ('Herantis'), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri ...

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

Ovarian cancer (OC) is a "silent killer" with an annual incidence of 11.2 per 100,000 and mortality of 7.6 per 100,000. Most cases are diagnosed at ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...